{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:25:57Z","timestamp":1716423957809},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,22]]},"DOI":"10.7759\/cureus.60833","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:09:10Z","timestamp":1716368950000},"source":"Crossref","is-referenced-by-count":0,"title":["Glofitamab-Associated Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Serial Seizures and Responding Positively to Antiseizure Drugs and Anakinra: A Case Report"],"prefix":"10.7759","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees JH","year":"2022","unstructured":"Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). The EBMT\/EHA CAR-T Cell Handbook. Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (ed): Springer, Cham, Switzerland; 2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2429-23","article-title":"Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer","volume":"63","author":"Tanaka T","year":"2024","unstructured":"Tanaka T, Taoka M, Makimoto G, et al.. Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer. Intern Med. 2024, 63:1261-7. 10.2169\/internalmedicine.2429-23","journal-title":"Intern Med"},{"key":"ref3","unstructured":"Glofitamab-GXBM (intravenous route). (2024). https.\/\/www.mayoclinic.org\/drugs-supplements\/glofitamab-gxbm-intravenous-route\/description\/drg-20552467#:~:text=Descr...."},{"key":"ref4","unstructured":"Product monograph including patient medication information Prcolumvi\u00ae glofitamab for injection concentrate for solution for intravenous infusion. (2023). https.\/\/assets.roche.com\/f\/173850\/x\/f54500f377\/columvi_pm_e.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi M","year":"2020","unstructured":"Pennisi M, Jain T, Santomasso BD, et al.. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020, 4:676-86. 10.1182\/bloodadvances.2019000952","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau N","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, et al.. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023, 29:430-7. 10.1016\/j.jtct.2023.04.001","journal-title":"Transplant Cell Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli M","year":"2022","unstructured":"Wehrli M, Gallagher K, Chen YB, et al.. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022, 10:e003847. 10.1136\/jitc-2021-003847","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-021-00780-w","article-title":"The critically ill CAR T-cell patient : relevant toxicities, their management and challenges in critical care (Article in German)","volume":"116","author":"Garcia Borrega J","year":"2021","unstructured":"Garcia Borrega J, Heindel K, Kochanek M, et al.. The critically ill CAR T-cell patient : relevant toxicities, their management and challenges in critical care (Article in German). Med Klin Intensivmed Notfmed. 2021, 116:121-8. 10.1007\/s00063-021-00780-w","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris EC","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022, 22:85-96. 10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlac121","article-title":"Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma","volume":"82","author":"Nie EH","year":"2023","unstructured":"Nie EH, Ahmadian SS, Bharadwaj SN, et al.. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. J Neuropathol Exp Neurol. 2023, 82:160-8. 10.1093\/jnen\/nlac121","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221140320","article-title":"Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting","volume":"29","author":"Lipe BC","year":"2023","unstructured":"Lipe BC, Renaud T. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting. J Oncol Pharm Pract. 2023, 29:1006-10. 10.1177\/10781552221140320","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","article-title":"Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy","volume":"10","author":"Amidi Y","year":"2022","unstructured":"Amidi Y, Eckhardt CA, Quadri SA, et al.. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022, 10:e005459. 10.1136\/jitc-2022-005459","journal-title":"J Immunother Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017, 377:2531-44. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings M","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al.. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021, 39:1959-70. 10.1200\/JCO.20.03175","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2312243","article-title":"An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas","volume":"24","author":"Polgarova K","year":"2024","unstructured":"Polgarova K, Trneny M. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas. Expert Opin Biol Ther. 2024, 24:7-13. 10.1080\/14712598.2024.2312243","journal-title":"Expert Opin Biol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2248390","article-title":"Neurological adverse effects of chimeric antigen receptor T-cell therapy","volume":"19","author":"Saleki K","year":"2023","unstructured":"Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol. 2023, 19:1361-83. 10.1080\/1744666X.2023.2248390","journal-title":"Expert Rev Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain MD","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023, 141:2430-42. 10.1182\/blood.2022017414","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30741","article-title":"Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome","volume":"71","author":"Shalabi H","year":"2024","unstructured":"Shalabi H, Harrison C, Yates B, Calvo KR, Lee DW, Shah NN. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome. Pediatr Blood Cancer. 2024, 71:e30741. 10.1002\/pbc.30741","journal-title":"Pediatr Blood Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51866","article-title":"Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG","volume":"10","author":"Eckhardt CA","year":"2023","unstructured":"Eckhardt CA, Sun H, Malik P, et al.. Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG. Ann Clin Transl Neurol. 2023, 10:1776-89. 10.1002\/acn3.51866","journal-title":"Ann Clin Transl Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1742-6723.14300","article-title":"Chimeric antigen receptor T-cell therapy: prospective observational study of unplanned emergency department presentations","volume":"35","author":"Bak GG","year":"2023","unstructured":"Bak GG, Micklethwaite K, Maddock K, Coggins A. Chimeric antigen receptor T-cell therapy: prospective observational study of unplanned emergency department presentations. Emerg Med Australas. 2023, 35:1034-7. 10.1111\/1742-6723.14300","journal-title":"Emerg Med Australas"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253276-glofitamab-associated-immune-effector-cell-associated-neurotoxicity-syndrome-icans-presenting-as-serial-seizures-and-responding-positively-to-antiseizure-drugs-and-anakinra-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:09:14Z","timestamp":1716368954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253276-glofitamab-associated-immune-effector-cell-associated-neurotoxicity-syndrome-icans-presenting-as-serial-seizures-and-responding-positively-to-antiseizure-drugs-and-anakinra-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.60833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}